DISCUSS

Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized phase II trial of the AIO working groups breast cancer and quality of life

II

interventionell

National

The treatment of this trial consists of endocrine therapy with or without CDK4/6 inhibitor. All substances are approved in Germany/Europe and, moreover, they are standard of care for patients with metastatic breast cancer. They will be prescribed by the investigator and administrated within their labels and according to clinical routine. For purpose of clarification, no study medication will be provided by the Sponsor. All components are available from several pharmaceutical companies (generic products) as well as in different formulations.

Status: In Rekrutierung

Zeitraum

2024

2026

Zentren

15

7

Auf Anfrage

Patienten

120

7

04.04.2024

Klinische Settings

IV

neoadjuvant

1st line, 2nd line

kurativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest

Kooperierende Fachgesellschaft(en)

AGO

Förderer

Hector Stiftung

Identifier

AIO-MAM-LQ-0223

2023-504141-31-00

Kontakt

Leitung

Prof. Dr. med. Thomas Decker

Ansprechpartner*in

Dr. Regina Eickhoff
Telefon +49 (0) 69 76014165
E-Mail eickhoff.regina@ikf-khnw.de